Photocure, the Bladder Cancer Company, has partnered with medtech manufacturer Richard Wolf to develop and commercialise a 4K LED high-definition (HD) reusable flexible blue light cystoscope.
The collaboration aims to bring advanced flexible blue light cystoscopy (BLC) equipment to the global market, enhancing outpatient treatment for bladder cancer with Hexvix/Cysview.
Go deeper with GlobalData
Hexvix/Cysview is a drug that enhances the visibility of cancer cells in the bladder during BLC, improving tumour detection and treatment outcomes.
Richard Wolf will develop the new BLC system with guidance from Photocure, leveraging the latter’s expertise in surveillance procedures and urology customer experience. The company will also own the new system and its intellectual property, and be responsible for obtaining market authorisations worldwide.
Both companies will share development and regulatory expenses for the HD flexible blue light system.
The partnership extends the existing relationship between Photocure and Richard Wolf, which includes co-promotion and market development efforts.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataPhotocure president and CEO Dan Schneider said: “Entering this partnership with Richard Wolf is a milestone for Photocure, and more importantly is the first step toward making high-definition BLC equipment in the surveillance setting consistently available for patients globally.
“We look forward to working with Richard Wolf on the development and anticipated commercialisation of a 4K high-definition blue light cystoscope, and bringing a cutting-edge and cost-effective solution to physicians and patients in our commercial territories as soon as possible.”
The two companies will co-promote the new system in the US, Europe, and other global markets.
Photocure will use its sales organisation to promote the system in North America and Europe while Richard Wolf distributors or commercial partners will handle promotion in other regions.
Photocure directly commercialises Cysview/Hexvix in the US and Europe, with strategic partnerships for commercialisation in other countries.
